Skip to content
DeeptechNavigator

Patent intelligence · Companies

Company patent strength

Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.

Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.

Why this page exists — and how to read it

Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.

Investors
High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
Founders & operators
These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
Corporate & R&D
Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.

💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.

Domestic (India)Foreign applicants
Portfolio sizeGrant rateLapsed

3,207 foreign filers with 5+ patents · page 7

#FilerPatentsGrantedLapsedPendingActive
301ALNYLAM PHARMACEUTICALS5211.9%1502022–2026
302CALB GROUP5211.9%0512023–2024
303CATALER521223.1%1392022–2026
304DAIICHI SANKYO5259.6%2452021–2026
305GENERAL ELECTRIC TECHNOLOGY52815.4%1432019–2025
306PRIMETALS TECHNOLOGIES AUSTRIA52713.5%0452022–2026
307SPECIALTY OPERATIONS FRANCE5247.7%0482010–2026
308TRANSPORTATION IP HOLDINGS5247.7%0482016–2025
309VERTEX PHARMACEUTICALS5247.7%4442020–2026
310CARL FREUDENBERG KG511427.5%2352022–2026
311CHIESI FARMACEUTICI5135.9%5432022–2026
312SNF GROUP5159.8%3432022–2026
313CARRIER50714%7362013–2024
314CHEVRON PHILLIPS CHEMICAL LP50612%0442022–2026
315CUMMINS POWER GENERATION50510%0452022–2025
316FISHER PAYKEL HEALTHCARE50714%2412020–2026
317SAINT GOBAIN ISOVER50510%1442022–2026
318DANIELI C OFFICINE MECCANICHE49816.3%0412022–2026
319MITSUI MINING SMELTING49918.4%1392022–2025
320VMI HOLLAND4912%3452022–2026
321INTERDIGITAL VC HOLDINGS FRANCE4800%2462022–2023
322LIFETECH SCIENTIFIC SHENZHEN481531.3%1322022–2026
323LUBRIZOL ADVANCED MATERIALS48714.6%5362022–2026
324NISSEI ASB MACHINE481327.1%0352022–2026
325RF360 SINGAPORE4812.1%0472023–2026
326STELLANTIS AUTO4800%0482024–2025
327VERTIV4836.3%0452022–2026
328WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY48816.7%0402021–2025
329ISCAR4712.1%1452021–2026
330JAPAN DISPLAY47817%4352022–2025
331KELLOGG BROWN ROOT471123.4%6302022–2026
332NHK SPRING47612.8%0412017–2026
333SULZER MANAGEMENT47919.1%3352021–2026
334ZHEJIANG DUNAN ARTIFICIAL ENVIRONMENT4724.3%0452022–2026
335AKTIEBOLAGET SKF4612.2%0452019–2026
336ALPLA WERKE ALWIN LEHNER KG4624.3%0442021–2026
337ARVINMERITOR TECHNOLOGY461021.7%0362022–2025
338ASTRAZENECA4636.5%2412012–2026
339EISAI R D MANAGEMENT4612.2%9362021–2026
340FUJI ELECTRIC461123.9%2332022–2025
341HON HAI PRECISION INDUSTRY4600%1452022–2025
342NIPPON SHOKUBAI461328.3%0332022–2026
343SHENZHEN TRANSSION HOLDINGS46919.6%3342019–2026
344UIPATH461430.4%0322021–2025
345WING AVIATION4600%0462023–2026
346BASELL POLIOLEFINE ITALIA S R L45920%5312022–2026
347BECTON DICKINSON FRANCE45817.8%0372021–2026
348BEIJING ROBOROCK INNOVATION TECHNOLOGY4512.2%0442023–2026
349FAURECIA INDIA4524.4%0432019–2024
350GIESECKE DEVRIENT CURRENCY TECHNOLOGY45511.1%3372022–2026
← PreviousNext →

Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →

Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →